| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyCellularComponent | SOSS complex | 1.19e-05 | 4 | 30 | 2 | GO:0070876 | |
| GeneOntologyCellularComponent | extrinsic component of plasma membrane | 4.24e-05 | 137 | 30 | 4 | GO:0019897 | |
| GeneOntologyCellularComponent | extrinsic component of membrane | 3.13e-04 | 230 | 30 | 4 | GO:0019898 | |
| Domain | NA-bd_OB_tRNA | 1.63e-04 | 12 | 30 | 2 | IPR004365 | |
| Domain | tRNA_anti-codon | 1.63e-04 | 12 | 30 | 2 | PF01336 | |
| Domain | GDS_CDC24_CS | 1.78e-03 | 39 | 30 | 2 | IPR001331 | |
| Domain | HMG_box | 3.27e-03 | 53 | 30 | 2 | PF00505 | |
| Domain | HMG_BOX_2 | 3.39e-03 | 54 | 30 | 2 | PS50118 | |
| Domain | HMG | 3.39e-03 | 54 | 30 | 2 | SM00398 | |
| Domain | - | 3.51e-03 | 55 | 30 | 2 | 1.10.30.10 | |
| Domain | DH_1 | 4.58e-03 | 63 | 30 | 2 | PS00741 | |
| Domain | HMG_box_dom | 4.87e-03 | 65 | 30 | 2 | IPR009071 | |
| Domain | RhoGEF | 5.32e-03 | 68 | 30 | 2 | SM00325 | |
| Domain | DH_2 | 5.63e-03 | 70 | 30 | 2 | PS50010 | |
| Domain | RhoGEF | 5.63e-03 | 70 | 30 | 2 | PF00621 | |
| Domain | DH-domain | 5.79e-03 | 71 | 30 | 2 | IPR000219 | |
| Domain | - | 5.79e-03 | 71 | 30 | 2 | 1.20.900.10 | |
| Domain | NA-bd_OB-fold | 7.83e-03 | 83 | 30 | 2 | IPR012340 | |
| Domain | WD40_repeat_dom | 1.18e-02 | 297 | 30 | 3 | IPR017986 | |
| Pubmed | SORBS1 ANK2 PRPF8 TIAM1 ARHGEF10 DSCAML1 BRWD3 RBCK1 NABP2 BACH1 | 7.00e-08 | 1285 | 30 | 10 | 35914814 | |
| Pubmed | 7.19e-07 | 2 | 30 | 2 | 36463112 | ||
| Pubmed | 7.19e-07 | 2 | 30 | 2 | 28813675 | ||
| Pubmed | NABP1, a novel RORgamma-regulated gene encoding a single-stranded nucleic-acid-binding protein. | 7.19e-07 | 2 | 30 | 2 | 16533169 | |
| Pubmed | 7.19e-07 | 2 | 30 | 2 | 34949193 | ||
| Pubmed | 7.19e-07 | 2 | 30 | 2 | 22427969 | ||
| Pubmed | 7.19e-07 | 2 | 30 | 2 | 35111387 | ||
| Pubmed | 7.19e-07 | 2 | 30 | 2 | 10636882 | ||
| Pubmed | 2.16e-06 | 3 | 30 | 2 | 27107424 | ||
| Pubmed | 4.31e-06 | 4 | 30 | 2 | 22496870 | ||
| Pubmed | Heme induces ubiquitination and degradation of the transcription factor Bach1. | 4.31e-06 | 4 | 30 | 2 | 17682061 | |
| Pubmed | The PHCCEx domain of Tiam1/2 is a novel protein- and membrane-binding module. | 4.31e-06 | 4 | 30 | 2 | 19893486 | |
| Pubmed | 7.18e-06 | 5 | 30 | 2 | 28270450 | ||
| Pubmed | Single strand DNA binding proteins 1 and 2 protect newly replicated telomeres. | 1.08e-05 | 6 | 30 | 2 | 23459151 | |
| Pubmed | HSSB1 and hSSB2 form similar multiprotein complexes that participate in DNA damage response. | 1.08e-05 | 6 | 30 | 2 | 19605351 | |
| Pubmed | SSB1/SSB2 Proteins Safeguard B Cell Development by Protecting the Genomes of B Cell Precursors. | 1.08e-05 | 6 | 30 | 2 | 31085591 | |
| Pubmed | Single-stranded DNA-binding protein hSSB1 is critical for genomic stability. | 1.51e-05 | 7 | 30 | 2 | 18449195 | |
| Pubmed | 1.51e-05 | 7 | 30 | 2 | 23299472 | ||
| Pubmed | 1.51e-05 | 7 | 30 | 2 | 17702746 | ||
| Pubmed | 1.92e-05 | 60 | 30 | 3 | 19075228 | ||
| Pubmed | SOSS complexes participate in the maintenance of genomic stability. | 2.01e-05 | 8 | 30 | 2 | 19683501 | |
| Pubmed | 3.22e-05 | 10 | 30 | 2 | 22940690 | ||
| Pubmed | 3.94e-05 | 11 | 30 | 2 | 19474150 | ||
| Pubmed | 5.26e-05 | 84 | 30 | 3 | 19165527 | ||
| Pubmed | 6.05e-05 | 88 | 30 | 3 | 21491433 | ||
| Pubmed | FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia. | 6.20e-05 | 497 | 30 | 5 | 36774506 | |
| Pubmed | The apical ectodermal ridge is a timer for generating distal limb progenitors. | 7.50e-05 | 15 | 30 | 2 | 18359901 | |
| Pubmed | 8.57e-05 | 16 | 30 | 2 | 24145799 | ||
| Pubmed | 9.70e-05 | 17 | 30 | 2 | 23408915 | ||
| Pubmed | 9.70e-05 | 17 | 30 | 2 | 19759019 | ||
| Pubmed | 1.22e-04 | 19 | 30 | 2 | 25956904 | ||
| Pubmed | An Alternative Splicing Program for Mouse Craniofacial Development. | 1.50e-04 | 21 | 30 | 2 | 33013468 | |
| Pubmed | 1.80e-04 | 23 | 30 | 2 | 23451260 | ||
| Pubmed | 1.92e-04 | 130 | 30 | 3 | 12421765 | ||
| Pubmed | Stromal Fat4 acts non-autonomously with Dchs1/2 to restrict the nephron progenitor pool. | 1.96e-04 | 24 | 30 | 2 | 26116661 | |
| Pubmed | 2.20e-04 | 1487 | 30 | 7 | 33957083 | ||
| Pubmed | 2.68e-04 | 28 | 30 | 2 | 32005677 | ||
| Pubmed | 2.80e-04 | 371 | 30 | 4 | 15747579 | ||
| Pubmed | Fgf10 is required for specification of non-sensory regions of the cochlear epithelium. | 2.88e-04 | 29 | 30 | 2 | 25624266 | |
| Pubmed | 2.88e-04 | 29 | 30 | 2 | 37948457 | ||
| Pubmed | 3.68e-04 | 1139 | 30 | 6 | 36417873 | ||
| Pubmed | 3.74e-04 | 33 | 30 | 2 | 32640236 | ||
| Pubmed | Single-cell transcriptomic analysis of mouse neocortical development. | 4.23e-04 | 170 | 30 | 3 | 30635555 | |
| Pubmed | Gonadal sex reversal in mutant Dax1 XY mice: a failure to upregulate Sox9 in pre-Sertoli cells. | 4.45e-04 | 36 | 30 | 2 | 15944188 | |
| Pubmed | Networks of bZIP protein-protein interactions diversified over a billion years of evolution. | 5.50e-04 | 40 | 30 | 2 | 23661758 | |
| Pubmed | 6.06e-04 | 42 | 30 | 2 | 29107558 | ||
| Pubmed | A central chaperone-like role for 14-3-3 proteins in human cells. | 7.83e-04 | 861 | 30 | 5 | 36931259 | |
| Interaction | CTDSPL interactions | 1.02e-05 | 92 | 30 | 4 | int:CTDSPL | |
| Cytoband | 21q22.11 | 7.62e-04 | 62 | 30 | 2 | 21q22.11 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr2p21 | 1.26e-03 | 80 | 30 | 2 | chr2p21 | |
| Coexpression | LIU_PROSTATE_CANCER_DN | 2.76e-09 | 493 | 30 | 9 | M19391 | |
| Coexpression | GSE40443_INDUCED_VS_TOTAL_TREG_UP | 2.93e-06 | 199 | 30 | 5 | M9198 | |
| Coexpression | GAVIN_FOXP3_TARGETS_CLUSTER_T4 | 4.49e-06 | 97 | 30 | 4 | M1729 | |
| Coexpression | GAVIN_FOXP3_TARGETS_CLUSTER_T4 | 5.06e-06 | 100 | 30 | 4 | MM1215 | |
| Coexpression | LIM_MAMMARY_STEM_CELL_UP | 1.48e-05 | 479 | 30 | 6 | M2573 | |
| Coexpression | LIM_MAMMARY_STEM_CELL_UP | 1.55e-05 | 483 | 30 | 6 | MM1082 | |
| Coexpression | GOBERT_CORE_OLIGODENDROCYTE_DIFFERENTIATION | 1.62e-05 | 43 | 30 | 3 | MM926 | |
| Coexpression | GOBERT_CORE_OLIGODENDROCYTE_DIFFERENTIATION | 1.62e-05 | 43 | 30 | 3 | M2370 | |
| Coexpression | ZHENG_BOUND_BY_FOXP3 | 1.84e-05 | 498 | 30 | 6 | M1741 | |
| Coexpression | ZHENG_BOUND_BY_FOXP3 | 2.03e-05 | 507 | 30 | 6 | MM1030 | |
| Coexpression | ASTON_MAJOR_DEPRESSIVE_DISORDER_DN | 3.24e-05 | 160 | 30 | 4 | M11011 | |
| Coexpression | KIM_GERMINAL_CENTER_T_HELPER_UP | 5.38e-05 | 64 | 30 | 3 | M1405 | |
| Coexpression | HE_LIM_SUN_FETAL_LUNG_C0_MID_AIRWAY_SMC_2_CELL | 6.20e-05 | 189 | 30 | 4 | M45678 | |
| Coexpression | GSE25087_TREG_VS_TCONV_FETUS_UP | 7.42e-05 | 198 | 30 | 4 | M4647 | |
| Coexpression | GSE13484_3H_UNSTIM_VS_YF17D_VACCINE_STIM_PBMC_DN | 7.42e-05 | 198 | 30 | 4 | M3267 | |
| Coexpression | JOHNSTONE_PARVB_TARGETS_3_UP | 1.22e-04 | 433 | 30 | 5 | M2240 | |
| Coexpression | SENESE_HDAC1_TARGETS_UP | 1.47e-04 | 451 | 30 | 5 | M14973 | |
| Coexpression | CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN | 1.70e-04 | 465 | 30 | 5 | M9192 | |
| Coexpression | KANG_AR_TARGETS_UP | 1.70e-04 | 17 | 30 | 2 | MM1297 | |
| Coexpression | KANG_AR_TARGETS_UP | 1.70e-04 | 17 | 30 | 2 | M2223 | |
| Coexpression | BOQUEST_STEM_CELL_UP | 2.15e-04 | 261 | 30 | 4 | M1834 | |
| Coexpression | SENESE_HDAC3_TARGETS_UP | 2.27e-04 | 495 | 30 | 5 | M8451 | |
| Coexpression | MALTA_CURATED_STEMNESS_MARKERS | 2.62e-04 | 21 | 30 | 2 | M30411 | |
| Coexpression | GAUTAM_EYE_IRIS_CILIARY_BODY_MEG3_HIGH_FIBROBLASTS | 2.91e-04 | 113 | 30 | 3 | M43610 | |
| Coexpression | BENPORATH_OCT4_TARGETS | 3.21e-04 | 290 | 30 | 4 | M17183 | |
| Coexpression | CHANDRAN_METASTASIS_DN | 4.44e-04 | 316 | 30 | 4 | M11615 | |
| Coexpression | MANNO_MIDBRAIN_NEUROTYPES_HRGL3 | 4.48e-04 | 574 | 30 | 5 | M39056 | |
| Coexpression | MARTINEZ_RB1_AND_TP53_TARGETS_UP | 6.50e-04 | 623 | 30 | 5 | M15896 | |
| Coexpression | BENPORATH_NANOG_TARGETS | 7.72e-04 | 988 | 30 | 6 | M6616 | |
| Coexpression | GSE13547_WT_VS_ZFX_KO_BCELL_UP | 8.47e-04 | 163 | 30 | 3 | M2997 | |
| Coexpression | TRAVAGLINI_LUNG_ALVEOLAR_FIBROBLAST_CELL | 8.62e-04 | 164 | 30 | 3 | M41676 | |
| Coexpression | HUANG_FOXA2_TARGETS_DN | 8.68e-04 | 38 | 30 | 2 | M16701 | |
| Coexpression | BURTON_ADIPOGENESIS_PEAK_AT_8HR | 9.14e-04 | 39 | 30 | 2 | M1641 | |
| Coexpression | HU_FETAL_RETINA_FIBROBLAST | 9.28e-04 | 385 | 30 | 4 | M39264 | |
| Coexpression | MARTINEZ_RB1_AND_TP53_TARGETS_UP | 1.02e-03 | 689 | 30 | 5 | MM1041 | |
| Coexpression | GSE8685_IL2_ACT_IL2_STARVED_VS_IL21_ACT_IL2_STARVED_CD4_TCELL_UP | 1.02e-03 | 174 | 30 | 3 | M333 | |
| Coexpression | MARTINEZ_RB1_TARGETS_UP | 1.03e-03 | 690 | 30 | 5 | M12224 | |
| Coexpression | BURTON_ADIPOGENESIS_PEAK_AT_8HR | 1.06e-03 | 42 | 30 | 2 | MM691 | |
| Coexpression | BENPORATH_NOS_TARGETS | 1.11e-03 | 179 | 30 | 3 | M14573 | |
| Coexpression | KHETCHOUMIAN_TRIM24_TARGETS_UP | 1.27e-03 | 46 | 30 | 2 | MM544 | |
| Coexpression | TRAVAGLINI_LUNG_OLR1_CLASSICAL_MONOCYTE_CELL | 1.27e-03 | 724 | 30 | 5 | M41700 | |
| Coexpression | SWEET_LUNG_CANCER_KRAS_DN | 1.30e-03 | 422 | 30 | 4 | M7396 | |
| Coexpression | KHETCHOUMIAN_TRIM24_TARGETS_UP | 1.33e-03 | 47 | 30 | 2 | M1399 | |
| Coexpression | HAN_SATB1_TARGETS_UP | 1.34e-03 | 425 | 30 | 4 | M9639 | |
| Coexpression | GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN | 1.36e-03 | 1102 | 30 | 6 | M2369 | |
| Coexpression | GSE19888_ADENOSINE_A3R_INH_PRETREAT_AND_ACT_BY_A3R_VS_A3R_INH_AND_TCELL_MEMBRANES_ACT_MAST_CELL_UP | 1.40e-03 | 194 | 30 | 3 | M7313 | |
| Coexpression | GSE2770_TGFB_AND_IL4_VS_IL4_TREATED_ACT_CD4_TCELL_6H_UP | 1.40e-03 | 194 | 30 | 3 | M6103 | |
| Coexpression | MARTINEZ_RB1_TARGETS_UP | 1.41e-03 | 741 | 30 | 5 | MM1037 | |
| Coexpression | GSE25088_CTRL_VS_IL4_AND_ROSIGLITAZONE_STIM_MACROPHAGE_UP | 1.42e-03 | 195 | 30 | 3 | M7926 | |
| Coexpression | GSE9509_LPS_VS_LPS_AND_IL10_STIM_IL10_KO_MACROPHAGE_20MIN_UP | 1.42e-03 | 195 | 30 | 3 | M6899 | |
| Coexpression | GSE29618_BCELL_VS_PDC_UP | 1.44e-03 | 196 | 30 | 3 | M4940 | |
| Coexpression | GSE29618_PRE_VS_DAY7_POST_LAIV_FLU_VACCINE_MONOCYTE_UP | 1.46e-03 | 197 | 30 | 3 | M4993 | |
| Coexpression | GSE15330_LYMPHOID_MULTIPOTENT_VS_GRANULOCYTE_MONOCYTE_PROGENITOR_IKAROS_KO_UP | 1.48e-03 | 198 | 30 | 3 | M7046 | |
| Coexpression | GSE3982_BASOPHIL_VS_NKCELL_UP | 1.48e-03 | 198 | 30 | 3 | M5561 | |
| Coexpression | GSE3982_MAC_VS_BASOPHIL_DN | 1.48e-03 | 198 | 30 | 3 | M5498 | |
| Coexpression | GSE37301_COMMON_LYMPHOID_PROGENITOR_VS_PRO_BCELL_UP | 1.48e-03 | 198 | 30 | 3 | M8866 | |
| Coexpression | KENNY_CTNNB1_TARGETS_UP | 1.50e-03 | 50 | 30 | 2 | M11067 | |
| Coexpression | GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN | 1.50e-03 | 1124 | 30 | 6 | MM1070 | |
| Coexpression | GSE24634_IL4_VS_CTRL_TREATED_NAIVE_CD4_TCELL_DAY5_DN | 1.50e-03 | 199 | 30 | 3 | M4635 | |
| Coexpression | GSE21033_CTRL_VS_POLYIC_STIM_DC_6H_UP | 1.50e-03 | 199 | 30 | 3 | M7712 | |
| Coexpression | GSE22140_GERMFREE_VS_SPF_ARTHRITIC_MOUSE_CD4_TCELL_DN | 1.50e-03 | 199 | 30 | 3 | M7645 | |
| Coexpression | GSE29949_MICROGLIA_VS_DC_BRAIN_UP | 1.50e-03 | 199 | 30 | 3 | M8399 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_6_7WK_UP | 1.50e-03 | 199 | 30 | 3 | MM991 | |
| Coexpression | HALLMARK_IL2_STAT5_SIGNALING | 1.50e-03 | 199 | 30 | 3 | M5947 | |
| Coexpression | GSE41176_WT_VS_TAK1_KO_ANTI_IGM_STIM_BCELL_6H_DN | 1.50e-03 | 199 | 30 | 3 | M9943 | |
| Coexpression | MCBRYAN_PUBERTAL_BREAST_6_7WK_UP | 1.50e-03 | 199 | 30 | 3 | M2155 | |
| Coexpression | GSE3982_MAST_CELL_VS_NKCELL_UP | 1.50e-03 | 199 | 30 | 3 | M5450 | |
| Coexpression | GSE20727_ROS_INH_VS_ROS_INH_AND_DNFB_ALLERGEN_TREATED_DC_UP | 1.50e-03 | 199 | 30 | 3 | M9252 | |
| Coexpression | GSE36078_WT_VS_IL1R_KO_LUNG_DC_AFTER_AD5_INF_DN | 1.50e-03 | 199 | 30 | 3 | M9288 | |
| Coexpression | GSE39110_DAY3_VS_DAY6_POST_IMMUNIZATION_CD8_TCELL_WITH_IL2_TREATMENT_DN | 1.50e-03 | 199 | 30 | 3 | M9283 | |
| Coexpression | GSE21670_UNTREATED_VS_TGFB_TREATED_STAT3_KO_CD4_TCELL_DN | 1.50e-03 | 199 | 30 | 3 | M7463 | |
| Coexpression | GSE31082_DN_VS_DP_THYMOCYTE_DN | 1.53e-03 | 200 | 30 | 3 | M5055 | |
| Coexpression | GSE32423_MEMORY_VS_NAIVE_CD8_TCELL_DN | 1.53e-03 | 200 | 30 | 3 | M5073 | |
| Coexpression | GSE13493_CD4INTCD8POS_VS_CD8POS_THYMOCYTE_UP | 1.53e-03 | 200 | 30 | 3 | M3316 | |
| Coexpression | GSE11961_MEMORY_BCELL_DAY40_VS_GERMINAL_CENTER_BCELL_DAY40_DN | 1.53e-03 | 200 | 30 | 3 | M9382 | |
| Coexpression | GSE22601_IMMATURE_CD4_SINGLE_POSITIVE_VS_DOUBLE_POSITIVE_THYMOCYTE_DN | 1.53e-03 | 200 | 30 | 3 | M6247 | |
| Coexpression | GSE21927_SPLEEN_C57BL6_VS_4T1_TUMOR_BALBC_MONOCYTES_DN | 1.53e-03 | 200 | 30 | 3 | M7595 | |
| Coexpression | GSE11961_MARGINAL_ZONE_BCELL_VS_GERMINAL_CENTER_BCELL_DAY7_DN | 1.53e-03 | 200 | 30 | 3 | M9321 | |
| Coexpression | GSE13484_UNSTIM_VS_YF17D_VACCINE_STIM_PBMC_DN | 1.53e-03 | 200 | 30 | 3 | M3279 | |
| Coexpression | GSE15330_LYMPHOID_MULTIPOTENT_VS_MEGAKARYOCYTE_ERYTHROID_PROGENITOR_UP | 1.53e-03 | 200 | 30 | 3 | M7031 | |
| Coexpression | GSE21063_WT_VS_NFATC1_KO_BCELL_DN | 1.53e-03 | 200 | 30 | 3 | M8261 | |
| Coexpression | GSE1432_CTRL_VS_IFNG_24H_MICROGLIA_UP | 1.53e-03 | 200 | 30 | 3 | M3407 | |
| Coexpression | GSE360_CTRL_VS_B_MALAYI_LOW_DOSE_MAC_UP | 1.53e-03 | 200 | 30 | 3 | M5168 | |
| Coexpression | HALLMARK_GLYCOLYSIS | 1.53e-03 | 200 | 30 | 3 | M5937 | |
| Coexpression | HALLMARK_MYOGENESIS | 1.53e-03 | 200 | 30 | 3 | M5909 | |
| Coexpression | HALLMARK_ESTROGEN_RESPONSE_LATE | 1.53e-03 | 200 | 30 | 3 | M5907 | |
| Coexpression | GSE42021_CD24HI_VS_CD24INT_TREG_THYMUS_DN | 1.53e-03 | 200 | 30 | 3 | M9586 | |
| Coexpression | GSE5542_IFNG_VS_IFNA_AND_IFNG_TREATED_EPITHELIAL_CELLS_24H_UP | 1.53e-03 | 200 | 30 | 3 | M6535 | |
| Coexpression | GSE5542_UNTREATED_VS_IFNA_TREATED_EPITHELIAL_CELLS_24H_UP | 1.53e-03 | 200 | 30 | 3 | M6524 | |
| Coexpression | GSE43700_UNTREATED_VS_IL10_TREATED_PBMC_DN | 1.53e-03 | 200 | 30 | 3 | M9623 | |
| Coexpression | GSE3982_BASOPHIL_VS_TH2_UP | 1.53e-03 | 200 | 30 | 3 | M5566 | |
| Coexpression | GSE32986_UNSTIM_VS_GMCSF_AND_CURDLAN_LOWDOSE_STIM_DC_DN | 1.53e-03 | 200 | 30 | 3 | M8620 | |
| Coexpression | GSE29618_MONOCYTE_VS_MDC_UP | 1.53e-03 | 200 | 30 | 3 | M4948 | |
| Coexpression | GSE15930_STIM_VS_STIM_AND_IFNAB_72H_CD8_T_CELL_DN | 1.53e-03 | 200 | 30 | 3 | M3646 | |
| Coexpression | GSE3203_HEALTHY_VS_INFLUENZA_INFECTED_LN_BCELL_DN | 1.53e-03 | 200 | 30 | 3 | M6791 | |
| Coexpression | GSE3982_DC_VS_TH2_UP | 1.53e-03 | 200 | 30 | 3 | M5484 | |
| Coexpression | GSE32164_RESTING_DIFFERENTIATED_VS_CMYC_INHIBITED_MACROPHAGE_DN | 1.53e-03 | 200 | 30 | 3 | M8531 | |
| Coexpression | GSE18203_CTRL_VS_INTRATUMORAL_CPG_INJ_MC38_TUMOR_DN | 1.53e-03 | 200 | 30 | 3 | M7208 | |
| Coexpression | GSE39110_UNTREATED_VS_IL2_TREATED_CD8_TCELL_DAY6_POST_IMMUNIZATION_DN | 1.53e-03 | 200 | 30 | 3 | M9285 | |
| Coexpression | GSE39916_B_CELL_SPLEEN_VS_PLASMA_CELL_BONE_MARROW_DN | 1.53e-03 | 200 | 30 | 3 | M9272 | |
| CoexpressionAtlas | DevelopingGonad_e18.5_testes_emap-11164_top-relative-expression-ranked_1000 | 1.24e-05 | 814 | 30 | 8 | gudmap_developingGonad_e18.5_testes_1000 | |
| CoexpressionAtlas | DevelopingGonad_P2_testes_emap-30171_top-relative-expression-ranked_1000 | 1.30e-05 | 819 | 30 | 8 | gudmap_developingGonad_P2_testes_1000 | |
| CoexpressionAtlas | dev gonad_e12.5_M_SertoliCell_Sox9_k-means-cluster#3_top-relative-expression-ranked_100 | 1.91e-05 | 37 | 30 | 3 | gudmap_dev gonad_e12.5_M_SertoliCell_Sox9_k3_100 | |
| CoexpressionAtlas | DevelopingGonad_e18.5_testes_emap-11164_top-relative-expression-ranked_500 | 2.06e-05 | 412 | 30 | 6 | gudmap_developingGonad_e18.5_testes_500 | |
| CoexpressionAtlas | DevelopingGonad_P2_testes_emap-30171_k-means-cluster#4_top-relative-expression-ranked_1000 | 7.76e-05 | 319 | 30 | 5 | gudmap_developingGonad_P2_testes_1000_k4 | |
| CoexpressionAtlas | dev gonad_e13.5_M_SertoliCell_Sox9_top-relative-expression-ranked_200 | 9.24e-05 | 170 | 30 | 4 | gudmap_dev gonad_e13.5_M_SertoliCell_Sox9_200 | |
| CoexpressionAtlas | DevelopingGonad_e16.5_testes_emap-8444_top-relative-expression-ranked_1000 | 1.16e-04 | 819 | 30 | 7 | gudmap_developingGonad_e16.5_testes_1000 | |
| CoexpressionAtlas | dev gonad_e13.5_F_MeioticGermCell_Oct_k-means-cluster#1_top-relative-expression-ranked_500 | 1.26e-04 | 12 | 30 | 2 | gudmap_dev gonad_e13.5_F_MeioticGermCell_Oct_k1_500 | |
| CoexpressionAtlas | dev gonad_e13.5_M_SertoliCell_Sox9_k-means-cluster#1_top-relative-expression-ranked_200 | 1.36e-04 | 71 | 30 | 3 | gudmap_dev gonad_e13.5_M_SertoliCell_Sox9_k1_200 | |
| CoexpressionAtlas | dev gonad_e13.5_M_SertoliCell_Sox9_top-relative-expression-ranked_100 | 2.09e-04 | 82 | 30 | 3 | gudmap_dev gonad_e13.5_M_SertoliCell_Sox9_100 | |
| CoexpressionAtlas | DevelopingGonad_e16.5_testes_emap-8444_k-means-cluster#4_top-relative-expression-ranked_500 | 2.32e-04 | 85 | 30 | 3 | gudmap_developingGonad_e16.5_testes_500_k4 | |
| CoexpressionAtlas | dev gonad_e12.5_M_SertoliCell_Sox9_top-relative-expression-ranked_100 | 2.58e-04 | 88 | 30 | 3 | gudmap_dev gonad_e12.5_M_SertoliCell_Sox9_100 | |
| CoexpressionAtlas | dev gonad_e13.5_M_SertoliCell_Sox9_top-relative-expression-ranked_500 | 3.22e-04 | 433 | 30 | 5 | gudmap_dev gonad_e13.5_M_SertoliCell_Sox9_500 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_2500_k-means-cluster#5 | 5.20e-04 | 743 | 30 | 6 | Facebase_RNAseq_ratio_e9.5_MaxillaryArch_vs_Mandibular_2500_K5 | |
| CoexpressionAtlas | DevelopingGonad_e18.5_testes_emap-11164_k-means-cluster#5_top-relative-expression-ranked_1000 | 5.79e-04 | 116 | 30 | 3 | gudmap_developingGonad_e18.5_testes_1000_k5 | |
| CoexpressionAtlas | FacebaseRNAseq_e8.5_Floor Plate_top-relative-expression-ranked_500 | 5.94e-04 | 495 | 30 | 5 | Facebase_RNAseq_e8.5_Floor Plate_500 | |
| CoexpressionAtlas | DevelopingGonad_P2_testes_emap-30171_k-means-cluster#2_top-relative-expression-ranked_500 | 5.94e-04 | 117 | 30 | 3 | gudmap_developingGonad_P2_testes_500_k2 | |
| ToppCell | 5'-Adult-LargeIntestine-Hematopoietic-T_cells-Treg|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.31e-07 | 181 | 30 | 5 | a6c8b33a392de3df2f179317e329e45d3d8c6f52 | |
| ToppCell | 10x5'-blood-Lymphocytic_T_CD4-Tregs|blood / Manually curated celltypes from each tissue | 1.42e-07 | 184 | 30 | 5 | 22c15ce30171c687ab564f4383ae74d38b759272 | |
| ToppCell | IPF-Lymphoid-T_Regulatory|Lymphoid / Disease state, Lineage and Cell class | 1.62e-07 | 189 | 30 | 5 | 7a260485c2a7c743c14d048e5e480ae0a9b8e32c | |
| ToppCell | COPD-Lymphoid-T_Regulatory|Lymphoid / Disease state, Lineage and Cell class | 1.71e-07 | 191 | 30 | 5 | 3ae18bc4e3dff49b5d5958da8ebc3f747274b69c | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 1.71e-07 | 191 | 30 | 5 | 08720998aa55131d7377c4c67c4c935865bd7d79 | |
| ToppCell | 3'_v3-lymph-node_spleen-Lymphocytic_T_CD4-Tregs|lymph-node_spleen / Manually curated celltypes from each tissue | 1.76e-07 | 192 | 30 | 5 | 91a4d06e8d1d1fe2ce5f72668108513bd2a72c4d | |
| ToppCell | normal_Lymph_Node-T/NK_cells-Treg|T/NK_cells / Location, Cell class and cell subclass | 1.80e-07 | 193 | 30 | 5 | 51fd629e91c85881c3231486d6d2fb2c65fcd77b | |
| ToppCell | tumor_Lymph_Node_/_Brain-T/NK_cells-Treg|T/NK_cells / Location, Cell class and cell subclass | 1.85e-07 | 194 | 30 | 5 | e46963d5f156526342ebc0fb9e767d266e812c42 | |
| ToppCell | mLN-T_cell-Treg|T_cell / Region, Cell class and subclass | 1.99e-07 | 197 | 30 | 5 | 3779489d57ebda33277c79cba037f4c73128c8ba | |
| ToppCell | T_cells-Treg_cells|World / Immune cells in Kidney/Urine in Lupus Nephritis | 1.99e-07 | 197 | 30 | 5 | de5448fcdf4e433fc167496413abe5d0c8a5c6d8 | |
| ToppCell | (1)_T_cell-(15)_Treg|(1)_T_cell / shred on Cell_type and subtype | 1.99e-07 | 197 | 30 | 5 | 6e7723e8b977be35c60cc11ac7cfa4f71339441e | |
| ToppCell | mLN-(1)_T_cell-(15)_Treg|mLN / shred on region, Cell_type, and subtype | 2.04e-07 | 198 | 30 | 5 | d4885f9c59b275e4e50dfcfb51c5351bebba1769 | |
| ToppCell | mLN-T_cell-Treg|mLN / Region, Cell class and subclass | 2.04e-07 | 198 | 30 | 5 | 6ce9681d1287632956176239f223e71abb8de44f | |
| ToppCell | Caecum-T_cell-Treg|T_cell / Region, Cell class and subclass | 2.04e-07 | 198 | 30 | 5 | 90a2a75ca078f7088b8739795a9b396113bcbe23 | |
| ToppCell | Adult-Endothelial-alveolar_capillary_endothelial_cell_(Cap2;_aerocyte)-D122|Adult / Lineage, Cell type, age group and donor | 5.11e-06 | 171 | 30 | 4 | bd20e85d36fa9d7ddc8afef6a1dea75efc9ee1dc | |
| ToppCell | COVID-19-Endothelial_cells-Capillary_endothelial_cells|COVID-19 / group, cell type (main and fine annotations) | 6.40e-06 | 181 | 30 | 4 | c5f9c92af1384d9089c65afdf41c6feb8345a3ae | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 6.40e-06 | 181 | 30 | 4 | 6a6bd8e020cb0929b6ecdcb55d467ad24fecfaf0 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_1|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 6.68e-06 | 183 | 30 | 4 | cfae90c309622b5d499e62a3a8a8b9746478d28d | |
| ToppCell | (1)_T_cells-(1)_T_regulatory|(1)_T_cells / Lung cell shreds - cell class (v4) and cell subclass (v4) | 6.83e-06 | 184 | 30 | 4 | 3cbf81757653652441843d85cb7ec1dcf25ca1b0 | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive|renal_medulla_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group | 6.83e-06 | 184 | 30 | 4 | d2bf0135eb56bb410997dccea39c5ede88a0617f | |
| ToppCell | Control-Lymphoid-T_Regulatory|Lymphoid / Disease state, Lineage and Cell class | 6.98e-06 | 185 | 30 | 4 | e481cacda0b6b25f5f0062b962df9a442053ac30 | |
| ToppCell | Adult-Endothelial-capillary_endothelial_cell_(Cap1)-D231|Adult / Lineage, Cell type, age group and donor | 6.98e-06 | 185 | 30 | 4 | 07f9f38f0739d7c830641723a38385550ac1ac92 | |
| ToppCell | Control-Endothelial_cells-Endothelial_cells_(other)|Control / group, cell type (main and fine annotations) | 7.13e-06 | 186 | 30 | 4 | c6075fe84226b370c5139066793844ad33ae2db1 | |
| ToppCell | Control-Endothelial_cells|Control / group, cell type (main and fine annotations) | 7.43e-06 | 188 | 30 | 4 | 3953b08abfea93468fc8d177bdb16ca7c6ffa1ab | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 7.75e-06 | 190 | 30 | 4 | 1121eb607a984c59fbffe7220837fc178745aa55 | |
| ToppCell | COVID-19-Endothelial_cells-Endothelial_cells_(general)|COVID-19 / group, cell type (main and fine annotations) | 7.75e-06 | 190 | 30 | 4 | 812e11314c76c0179fbe5a9bea29b41ce5cbc93d | |
| ToppCell | (1)_T_cells-(1)_T_CD4_fh|(1)_T_cells / Spleen cell shreds - cell class (v1) and cell subclass (v1) | 7.75e-06 | 190 | 30 | 4 | 120ca702600373c208a3d032fede0a040736e5cf | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 7.75e-06 | 190 | 30 | 4 | 048b581e3f7ea9fc2f87c0532974bba85c7292c2 | |
| ToppCell | COVID-19-Endothelial_cells|COVID-19 / group, cell type (main and fine annotations) | 7.75e-06 | 190 | 30 | 4 | 9fbd92cd6d4683b2490504d29c43cf42020433d4 | |
| ToppCell | (1)_T_CD4_fh|World / Spleen cell shreds - cell class (v1) and cell subclass (v1) | 7.91e-06 | 191 | 30 | 4 | 66ddff9a99092cb384b9fb2a3ba95ddbebed67cc | |
| ToppCell | tumor_Lung-T/NK_cells-Exhausted_Tfh|tumor_Lung / Location, Cell class and cell subclass | 7.91e-06 | 191 | 30 | 4 | 3e259eba83f8159d1a1a96b98d0e867fe547c5e7 | |
| ToppCell | nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 7.91e-06 | 191 | 30 | 4 | 6688cee34beee4f151ac17fccbc9c26a9aad72e1 | |
| ToppCell | nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 8.08e-06 | 192 | 30 | 4 | 99ce9e3c4c50cf64ebb62145f2b5420efa0db309 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 8.08e-06 | 192 | 30 | 4 | 3d0cb19f037f604253d7d728689aeaa94251e92b | |
| ToppCell | 10x5'-lymph-node_spleen-Lymphocytic_T_CD4-Tregs|lymph-node_spleen / Manually curated celltypes from each tissue | 8.08e-06 | 192 | 30 | 4 | 04bd6e135733570e877af9460f87379ed0a5c5f8 | |
| ToppCell | ILEUM-non-inflamed-(1)_T_cell-(1)_TFH-like|(1)_T_cell / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 8.08e-06 | 192 | 30 | 4 | 0f9cae41bb9bc9366efe9eb48e26b3e80c642879 | |
| ToppCell | normal_Lymph_Node-T/NK_cells-Treg|normal_Lymph_Node / Location, Cell class and cell subclass | 8.08e-06 | 192 | 30 | 4 | d2c2a98d331522a3ab7973bfaf4396ef4d684888 | |
| ToppCell | LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 8.08e-06 | 192 | 30 | 4 | deeecd26972241846b4cb998edf0c7a87ff0c4df | |
| ToppCell | nucseq-Endothelial-Endothelial_Vascular-Endothelial_capillary|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 8.24e-06 | 193 | 30 | 4 | f582e939e3e08a8a3f71deec78c33715be8faa51 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 8.24e-06 | 193 | 30 | 4 | fb28717fadd06c3840636d25409ce80c9254bd34 | |
| ToppCell | LPS-IL1RA-Endothelial-Endothelial-Activated_Alv_Cap|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 8.24e-06 | 193 | 30 | 4 | a3636c35ed25aabe2f1aba016c9fe125327bbfaf | |
| ToppCell | CF-Lymphoid-B_cell|Lymphoid / Disease state, Lineage and Cell class | 8.24e-06 | 193 | 30 | 4 | 7ebf20344a9a154fd2cffa281526867fcf0aded3 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 8.41e-06 | 194 | 30 | 4 | 60622bd2f75bfe4c37f721cb12f03dab33f2f58d | |
| ToppCell | 10x3'2.3-week_17-19-Myeloid_neutrophil-granulo-eo/baso/mast-basophil|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 8.41e-06 | 194 | 30 | 4 | 5da8873cddff582e5693b32fd3aaebc102f65fc0 | |
| ToppCell | 10x5'-GI_small-bowel-Lymphocytic_T_CD4|GI_small-bowel / Manually curated celltypes from each tissue | 8.41e-06 | 194 | 30 | 4 | 4547b57669be5d4f0de55175802ee04372288a6a | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 8.41e-06 | 194 | 30 | 4 | 6e13549f697f7478b34fe71f7dd9d63c5d3db22e | |
| ToppCell | ILEUM-inflamed-(1)_T_cell-(1)_Tregs|(1)_T_cell / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 8.41e-06 | 194 | 30 | 4 | 0396457834bbfed8d0b9b2ddaaecd9f28e1d56ed | |
| ToppCell | droplet-Limb_Muscle-MUSCLE|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.41e-06 | 194 | 30 | 4 | e3d63874111d1e8da3977329426e4dcf68d6de87 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 8.41e-06 | 194 | 30 | 4 | 89b706af2b25991fc2707eb24f49ba6ff3ae01f7 | |
| ToppCell | 3'-Pediatric_IBD-SmallIntestine-Hematopoietic-T_cells-Tfh|Pediatric_IBD / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 8.58e-06 | 195 | 30 | 4 | ea83c3c93ec4e09029185508bdbd6d9cc5e441d5 | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_1_cell|Adult / Lineage, Cell type, age group and donor | 8.58e-06 | 195 | 30 | 4 | 61c9e09fc84d1012e472185d70ad0a06cee30d6e | |
| ToppCell | COVID-19-Fibroblasts-Alveolar_FB|COVID-19 / group, cell type (main and fine annotations) | 8.58e-06 | 195 | 30 | 4 | 603050beeb33c331d4b2e3fa46cae3f3e0e4bdc7 | |
| ToppCell | tumor_Lung-T/NK_cells-Treg|T/NK_cells / Location, Cell class and cell subclass | 8.58e-06 | 195 | 30 | 4 | dd112ef3f8bd0790719827b6bb120918687afdff | |
| ToppCell | 3'-Child04-06-SmallIntestine-Hematopoietic-T_cells-Tfh|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 8.58e-06 | 195 | 30 | 4 | b2ecab35db438c82872cd16a6e9f013475e559ef | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_1_cell-D122|Adult / Lineage, Cell type, age group and donor | 8.58e-06 | 195 | 30 | 4 | aa0add081881d349099d12efca5cdee098038d4e | |
| ToppCell | critical-Lymphoid-Treg|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 8.76e-06 | 196 | 30 | 4 | 861665912eb0538b083d3eee77190925b3a43c24 | |
| ToppCell | nucseq-Endothelial-Endothelial_Vascular|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 8.76e-06 | 196 | 30 | 4 | 686533fd3fba8e4df96b9dd1307e870e89db4332 | |
| ToppCell | IPF-Endothelial-VE_Capillary_B|Endothelial / Disease state, Lineage and Cell class | 8.76e-06 | 196 | 30 | 4 | 8f0f72ead06abe02b575e443552eacc2151077ef | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 8.94e-06 | 197 | 30 | 4 | 94a9603cbd3516fbcce871909693b88f20d41713 | |
| ToppCell | NS-critical-d_07-13-Myeloid-Neutrophil|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 8.94e-06 | 197 | 30 | 4 | f38037dfa6c33e9336130d0cc65eaba0f120efb9 | |
| ToppCell | COVID-19-lung-Fibroblast|lung / Disease (COVID-19 only), tissue and cell type | 9.12e-06 | 198 | 30 | 4 | df3de77216f5c5d6141ec44d01c56b942f611838 | |
| ToppCell | NS-critical-d_07-13-Myeloid|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 9.12e-06 | 198 | 30 | 4 | 08bc3f63a5c5b65bff10aadebdaa5e7f192cda01 | |
| ToppCell | critical-Myeloid-Neutrophil|critical / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 9.12e-06 | 198 | 30 | 4 | 4da73dc3acb29d70b160903600d2bf7fdab34333 | |
| ToppCell | Caecum-(1)_T_cell-(15)_Treg|Caecum / shred on region, Cell_type, and subtype | 9.30e-06 | 199 | 30 | 4 | 12c22b07a231c9dc548e9dc37e0a60296a4a6273 | |
| ToppCell | NS-control-d_0-4-Epithelial-Secretory|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 9.30e-06 | 199 | 30 | 4 | 32bdfff40fd442b88489c8b0f79af3927a51a03c | |
| ToppCell | ILEUM-inflamed-(8)_Fibroblasts|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 9.30e-06 | 199 | 30 | 4 | 3a3e2bb21cd0293622b1a975263e918d9ba24265 | |
| ToppCell | Caecum-T_cell-Treg|Caecum / Region, Cell class and subclass | 9.30e-06 | 199 | 30 | 4 | ab0b32c077ac26d32a293dcf686af6984980793f | |
| ToppCell | critical|World / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 9.30e-06 | 199 | 30 | 4 | 16c55cb8a0e740342009965f0eddfb0ed2858fab | |
| ToppCell | control-Epithelial-Secretory|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 9.30e-06 | 199 | 30 | 4 | 3d01f90ffd271ca00129192787e4921bdca7e01e | |
| ToppCell | control-Epithelial-Secretory|control / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 9.30e-06 | 199 | 30 | 4 | 262e5b8a52c8ddb0b47048c786e8bdb7158e1b9a | |
| ToppCell | LPS_IL1RA_TNF-Endothelial-Endothelial-Alv_Cap|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 9.49e-06 | 200 | 30 | 4 | b7533c571eeea0cb3678e1a57d3dc036fa8d0f49 | |
| ToppCell | LPS_IL1RA-Endothelial-Endothelial-Alv_Cap|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 9.49e-06 | 200 | 30 | 4 | 7034f57e282982c19c13ee8ab78eabaffa069e30 | |
| ToppCell | Tracheal-NucSeq-Stromal-Chondrocytic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 9.49e-06 | 200 | 30 | 4 | b5a54b9baf79aea01f76a161f0a39bbe87eb4945 | |
| ToppCell | LPS_anti-TNF-Endothelial-Endothelial-Activated_Alv_Cap|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 9.49e-06 | 200 | 30 | 4 | bcd1cc96197929d6011903803b6f4ccdcf52b4ce | |
| ToppCell | Bronchial-NucSeq-Stromal-Fibroblastic-Fibro_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 9.49e-06 | 200 | 30 | 4 | e8462395fee0a532d1e7ec7f1795f28c42af6541 | |
| ToppCell | LPS_only-Endothelial-Endothelial-Alv_Cap|LPS_only / Treatment groups by lineage, cell group, cell type | 9.49e-06 | 200 | 30 | 4 | 432384faeade8e609154fab3d96c955a8ec868dd | |
| ToppCell | Tracheal-NucSeq-Stromal-Chondrocytic-Chondrocyte|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 9.49e-06 | 200 | 30 | 4 | f5bd0b30e478dac09f68c46b0781f5f2e7e3c693 | |
| ToppCell | LPS_IL1RA-Endothelial-Endothelial-Activated_Alv_Cap|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 9.49e-06 | 200 | 30 | 4 | 79e51afb57ca38aacebd0298e5e727b55c0cfff9 | |
| ToppCell | LPS_anti-TNF-Endothelial-Endothelial-Alv_Cap|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 9.49e-06 | 200 | 30 | 4 | 66f7e8ee63c828f17468e79a4b816346b33e8980 | |
| ToppCell | frontal_cortex-Non-neuronal-oligodendrocyte-Oligo-Oligo_Synpr|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.06e-04 | 137 | 30 | 3 | b03f19b233c1c809f2cd2b4a7642eeaf254a6289 | |
| ToppCell | facs-Pancreas-Exocrine-18m-Epithelial-nan|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.06e-04 | 137 | 30 | 3 | e9b88ad86b75454a8292a94879c5b665adc42744 | |
| ToppCell | primary_visual_cortex|World / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.15e-04 | 141 | 30 | 3 | 605d7b28e99c943f64b4095855a6f9f70e92cb09 | |
| ToppCell | mild_COVID-19_(asymptomatic)-Treg|mild_COVID-19_(asymptomatic) / disease group, cell group and cell class (v2) | 1.25e-04 | 145 | 30 | 3 | 2d0903009e918500facfd017ff31f2cec1e76131 | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0.5|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 1.27e-04 | 146 | 30 | 3 | cffa91d76606f74553d81150adbb23b003746316 | |
| ToppCell | 390C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0.5|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells) | 1.46e-04 | 153 | 30 | 3 | e7d20c88466ff81db613869cf7a6a4bb95fd6c2f | |
| ToppCell | frontal_cortex-Neuronal-GABAergic_neuron-Lamp5-Lamp5_Plch2_Dock5|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.58e-04 | 157 | 30 | 3 | 516903469756c5fabfdf56d7bd59b3bdd7b44e39 | |
| ToppCell | Bronchial-10x5prime-Stromal-Myofibroblastic-Muscle_smooth_airway_ASM|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.64e-04 | 159 | 30 | 3 | 7cda111bb98f1241989e49d490bdf51a712ea589 | |
| ToppCell | Control-Endothelial_cells-Inflamed_endothelial_cells|Control / group, cell type (main and fine annotations) | 1.67e-04 | 160 | 30 | 3 | 958256e3d3836160763b82bb48f794087918d935 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-G-|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 1.67e-04 | 160 | 30 | 3 | 0293b244c063a62819690bf22bbc2681f8d15252 | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic-precursor_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.67e-04 | 160 | 30 | 3 | c381ec6be8cf887861cc18f831a20db42f953fe1 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-G|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 1.67e-04 | 160 | 30 | 3 | 3eaae86fa08f7651021316f8e5811bf48055591e | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic-pre_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.67e-04 | 160 | 30 | 3 | 25c8f3d2a6d14ff0ca0b965fce89d3ff22f40585 | |
| ToppCell | AT1-AT2_cells-IPF_01|World / lung cells shred on cell class, cell subclass, sample id | 1.73e-04 | 162 | 30 | 3 | 57d627259d27f39885bf416d74bcb6656db6e27b | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c04-ANXA2|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.76e-04 | 163 | 30 | 3 | ce07bc424ef99c547588b07f5c8b39ff0773ca9b | |
| ToppCell | primary_visual_cortex-Neuronal-GABAergic_neuron-Lamp5|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.76e-04 | 163 | 30 | 3 | 8d17f44faf0549fe71a9a45f811f50d767275414 | |
| ToppCell | 367C-Lymphocytic-NK_cells-NK_cell_B2|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 1.76e-04 | 163 | 30 | 3 | 6c4d4c55fc8a731acca13c1ba7287f238a9d81e0 | |
| ToppCell | frontal_cortex-Neuronal-GABAergic_neuron-Lamp5|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.80e-04 | 164 | 30 | 3 | 08819970174a3eb4eee8e1e675075828665b845e | |
| ToppCell | Adult-Mesenchymal-myofibroblast_cell-D231|Adult / Lineage, Cell type, age group and donor | 1.80e-04 | 164 | 30 | 3 | 3d8ff70fe5582d1fb56b338be8b76fa1428b3657 | |
| ToppCell | NS-moderate-d_16-33-Myeloid-Mast_cell|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 1.80e-04 | 164 | 30 | 3 | 35c673380f75cb4bfe080089bc723c4373bcc7a5 | |
| ToppCell | T_cells-TFH-like_cells|World / Immune cells in Kidney/Urine in Lupus Nephritis | 1.80e-04 | 164 | 30 | 3 | b10cf59f4cc37ca6cd0ecf71d7de278cc2bdd8b5 | |
| Drug | Trichlormethiazide [133-67-5]; Down 200; 10.6uM; PC3; HT_HG-U133A | 5.24e-06 | 195 | 30 | 5 | 4198_DN | |
| Drug | Guanethidine sulfate [60-02-6]; Up 200; 13.4uM; MCF7; HT_HG-U133A | 5.37e-06 | 196 | 30 | 5 | 3171_UP | |
| Drug | Sertaconazole nitrate [99592-39-9]; Up 200; 8uM; PC3; HT_HG-U133A | 5.51e-06 | 197 | 30 | 5 | 4475_UP | |
| Drug | Todralazine hydrochloride [3778-76-5]; Up 200; 14.8uM; PC3; HT_HG-U133A | 5.65e-06 | 198 | 30 | 5 | 5087_UP | |
| Drug | thioridazine hydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A_EA | 4.93e-05 | 155 | 30 | 4 | 1068_UP | |
| Drug | 15d-PGJ2; Up 200; 10uM; MCF7; HT_HG-U133A | 9.20e-05 | 182 | 30 | 4 | 6990_UP | |
| Drug | 17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A | 9.40e-05 | 183 | 30 | 4 | 6985_UP | |
| Drug | Dobutamine hydrochloride [49745-95-1]; Up 200; 11.8uM; PC3; HT_HG-U133A | 9.80e-05 | 185 | 30 | 4 | 6286_UP | |
| Drug | Progesterone [57-83-0]; Down 200; 12.8uM; HL60; HT_HG-U133A | 1.00e-04 | 186 | 30 | 4 | 2426_DN | |
| Drug | (+)-Isoproterenol (+)-bitartrate salt [14638-70-1]; Up 200; 11uM; HL60; HT_HG-U133A | 1.04e-04 | 188 | 30 | 4 | 3046_UP | |
| Drug | Sanguinarine [2447-54-3]; Down 200; 12uM; MCF7; HT_HG-U133A | 1.11e-04 | 191 | 30 | 4 | 4168_DN | |
| Drug | Deptropine citrate [2169-75-7]; Up 200; 7.6uM; PC3; HT_HG-U133A | 1.13e-04 | 192 | 30 | 4 | 5118_UP | |
| Drug | Pramoxine hydrochloride [637-58-1]; Down 200; 12.2uM; MCF7; HT_HG-U133A | 1.13e-04 | 192 | 30 | 4 | 6054_DN | |
| Drug | estradiol; Up 200; 0.01uM; MCF7; HT_HG-U133A | 1.13e-04 | 192 | 30 | 4 | 5955_UP | |
| Drug | Probenecid [57-66-9]; Down 200; 14uM; MCF7; HT_HG-U133A | 1.15e-04 | 193 | 30 | 4 | 2825_DN | |
| Drug | Parbendazole [14255-87-9]; Down 200; 16.2uM; PC3; HT_HG-U133A | 1.15e-04 | 193 | 30 | 4 | 3799_DN | |
| Drug | Glycocholic acid [475-31-0]; Down 200; 8.6uM; MCF7; HT_HG-U133A | 1.18e-04 | 194 | 30 | 4 | 5316_DN | |
| Drug | Nifedipine [21829-25-4]; Up 200; 11.6uM; PC3; HT_HG-U133A | 1.18e-04 | 194 | 30 | 4 | 7303_UP | |
| Drug | Chloramphenicol [56-75-7]; Down 200; 12.4uM; PC3; HT_HG-U133A | 1.18e-04 | 194 | 30 | 4 | 5047_DN | |
| Drug | S(+)-Terguride [37686-84-3]; Up 200; 11.8uM; PC3; HT_HG-U133A | 1.20e-04 | 195 | 30 | 4 | 6299_UP | |
| Drug | Mexiletine hydrochloride [5370-01-4]; Up 200; 18.6uM; HL60; HT_HG-U133A | 1.20e-04 | 195 | 30 | 4 | 2364_UP | |
| Drug | Oxybutynin chloride [1508-65-2]; Down 200; 10.2uM; MCF7; HT_HG-U133A | 1.20e-04 | 195 | 30 | 4 | 6770_DN | |
| Drug | Bisoprolol fumarate; Down 200; 9uM; PC3; HT_HG-U133A | 1.22e-04 | 196 | 30 | 4 | 6748_DN | |
| Drug | Procainamide hydrochloride [614-39-1]; Up 200; 14.8uM; PC3; HT_HG-U133A | 1.22e-04 | 196 | 30 | 4 | 4602_UP | |
| Drug | Trimipramine maleate salt [521-78-8]; Down 200; 9.8uM; PC3; HT_HG-U133A | 1.22e-04 | 196 | 30 | 4 | 4083_DN | |
| Drug | Cefsulodin sodium salt [52152-93-9]; Up 200; 7.2uM; HL60; HT_HG-U133A | 1.22e-04 | 196 | 30 | 4 | 2988_UP | |
| Drug | Bupivacaine hydrochloride [18010-40-7]; Up 200; 12.4uM; PC3; HT_HG-U133A | 1.22e-04 | 196 | 30 | 4 | 5112_UP | |
| Drug | Dimethadione [695-53-4]; Down 200; 31uM; HL60; HT_HG-U133A | 1.22e-04 | 196 | 30 | 4 | 3029_DN | |
| Drug | Rapamycin; Down 200; 0.1uM; HL60; HT_HG-U133A | 1.22e-04 | 196 | 30 | 4 | 2667_DN | |
| Drug | Furaltadone hydrochloride [3759-92-0]; Down 200; 11uM; MCF7; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 3838_DN | |
| Drug | Dimethisoquin hydrochloride [2773-92-4]; Down 200; 13uM; PC3; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 4207_DN | |
| Drug | Serotonin hydrochloride [153-98-0]; Down 200; 18.8uM; PC3; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 4673_DN | |
| Drug | CP-320650-01 [172079-28-6]; Down 200; 10uM; PC3; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 4557_DN | |
| Drug | Sulfabenzamide [127-71-9]; Down 200; 14.4uM; MCF7; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 2814_DN | |
| Drug | Lactobionic acid [96-82-2]; Up 200; 11.2uM; PC3; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 6605_UP | |
| Drug | Clonidine hydrochloride [4205-91-8]; Up 200; 15uM; PC3; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 4478_UP | |
| Drug | Propranolol hydrochloride [318-98-9]; Up 200; 13.6uM; PC3; HT_HG-U133A | 1.25e-04 | 197 | 30 | 4 | 6759_UP | |
| Drug | Cyclopenthiazide [742-20-1]; Up 200; 10.6uM; HL60; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 2905_UP | |
| Drug | LY 294002; Up 200; 0.1uM; MCF7; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 6976_UP | |
| Drug | Lymecycline [992-21-2]; Up 200; 6.6uM; PC3; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 7291_UP | |
| Drug | Triamterene [396-01-0]; Up 200; 15.8uM; PC3; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 7307_UP | |
| Drug | Bemegride [64-65-3]; Down 200; 25.8uM; HL60; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 3051_DN | |
| Drug | Sulfisoxazole [127-69-5]; Down 200; 15uM; PC3; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 4661_DN | |
| Drug | Rilmenidine hemifumarate [54187-04-1]; Up 200; 8.4uM; PC3; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 5107_UP | |
| Drug | Reserpine [50-55-5]; Down 200; 6.6uM; PC3; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 4203_DN | |
| Drug | Bumetanide [28395-03-1]; Up 200; 11uM; PC3; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 5117_UP | |
| Drug | Cisapride [81098-60-4]; Down 200; 8.6uM; MCF7; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 3305_DN | |
| Drug | Spectinomycin dihydrochloride [21736-83-4]; Down 200; 9.8uM; PC3; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 4187_DN | |
| Drug | Meclofenoxate hydrochloride [3685-84-5]; Down 200; 13.6uM; PC3; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 3707_DN | |
| Drug | Heptaminol hydrochloride [543-15-7]; Up 200; 22uM; PC3; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 7313_UP | |
| Drug | Paroxetine maleate [64006-44-6]; Up 200; 1uM; MCF7; HT_HG-U133A | 1.27e-04 | 198 | 30 | 4 | 4378_UP | |
| Drug | Meclofenoxate hydrochloride [3685-84-5]; Up 200; 13.6uM; PC3; HT_HG-U133A | 1.30e-04 | 199 | 30 | 4 | 3707_UP | |
| Drug | Tropine [120-29-6]; Up 200; 28.4uM; PC3; HT_HG-U133A | 1.30e-04 | 199 | 30 | 4 | 5790_UP | |
| Drug | C75; Up 200; 10uM; MCF7; HT_HG-U133A | 1.30e-04 | 199 | 30 | 4 | 6394_UP | |
| Drug | Clozapine [5786-21-0]; Down 200; 12.2uM; PC3; HT_HG-U133A | 1.30e-04 | 199 | 30 | 4 | 4670_DN | |
| Drug | Sulpiride [15676-16-1]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 1.30e-04 | 199 | 30 | 4 | 4389_UP | |
| Drug | Lobeline alpha (-) hydrochoride [134-63-4]; Down 200; 10.6uM; PC3; HT_HG-U133A | 1.30e-04 | 199 | 30 | 4 | 5784_DN | |
| Drug | Austricine [10180-88-8]; Down 200; 14.2uM; PC3; HT_HG-U133A | 1.32e-04 | 200 | 30 | 4 | 4213_DN | |
| Drug | Loperamide hydrochloride [34552-83-5]; Down 200; 7.8uM; PC3; HT_HG-U133A | 1.32e-04 | 200 | 30 | 4 | 4672_DN | |
| Drug | methylselenic acid | 1.86e-04 | 412 | 30 | 5 | ctd:C008493 | |
| Drug | dibromoacetic acid | 2.83e-04 | 19 | 30 | 2 | CID000012433 | |
| Drug | Methylcholanthrene | 3.17e-04 | 1034 | 30 | 7 | ctd:D008748 | |
| Drug | mercuric bromide | 4.04e-04 | 1076 | 30 | 7 | ctd:C042720 | |
| Drug | pyrachlostrobin | 5.72e-04 | 811 | 30 | 6 | ctd:C513428 | |
| Drug | 1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine | 9.17e-04 | 34 | 30 | 2 | ctd:C000591541 | |
| Drug | Asbestos, Crocidolite | 9.46e-04 | 1241 | 30 | 7 | ctd:D017638 | |
| Drug | Sb-H | 1.03e-03 | 36 | 30 | 2 | CID005289334 | |
| Drug | AC1L98DX | 1.15e-03 | 38 | 30 | 2 | CID000439957 | |
| Drug | ON 01910 | 1.25e-03 | 162 | 30 | 3 | ctd:C507134 | |
| Drug | fluphenazine dihydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A_EA | 1.48e-03 | 172 | 30 | 3 | 1017_UP | |
| Drug | Parthenolide [20554-84-1]; Up 200; 16.2uM; PC3; HT_HG-U133A | 1.51e-03 | 173 | 30 | 3 | 5105_UP | |
| Drug | Chloroprene | 1.53e-03 | 1348 | 30 | 7 | ctd:D002737 | |
| Drug | Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A | 1.63e-03 | 178 | 30 | 3 | 4483_UP | |
| Drug | Alexidine dihydrochloride [22573-93-9]; Up 200; 6.8uM; MCF7; HT_HG-U133A | 1.66e-03 | 179 | 30 | 3 | 4721_UP | |
| Drug | Cephaeline dihydrochloride heptahydrate [6487-30-5]; Down 200; 6uM; MCF7; HT_HG-U133A | 1.69e-03 | 180 | 30 | 3 | 3290_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A | 1.71e-03 | 181 | 30 | 3 | 3688_UP | |
| Drug | STOCK1N-35696; Up 200; 15uM; MCF7; HT_HG-U133A | 1.74e-03 | 182 | 30 | 3 | 6577_UP | |
| Drug | LY 294002; Down 200; 10uM; HL60; HT_HG-U133A | 1.77e-03 | 183 | 30 | 3 | 2696_DN | |
| Drug | 17-AAG; Up 200; 1uM; HL60; HT_HG-U133A | 1.80e-03 | 184 | 30 | 3 | 2686_UP | |
| Drug | CP-690334-01 [459212-38-5]; Up 200; 10uM; MCF7; HT_HG-U133A | 1.85e-03 | 186 | 30 | 3 | 4380_UP | |
| Drug | 0297417-0002B [362658-29-5]; Up 200; 10uM; MCF7; HT_HG-U133A | 1.85e-03 | 186 | 30 | 3 | 6900_UP | |
| Drug | 0297417-0002B [362658-29-5]; Up 200; 10uM; MCF7; HT_HG-U133A | 1.88e-03 | 187 | 30 | 3 | 6902_UP | |
| Drug | Methotrexate [59-05-2]; Up 200; 8.8uM; MCF7; HT_HG-U133A | 1.88e-03 | 187 | 30 | 3 | 5419_UP | |
| Drug | troglitazone; Up 200; 10uM; MCF7; HT_HG-U133A_EA | 1.88e-03 | 187 | 30 | 3 | 1070_UP | |
| Drug | trifluoperazine dihydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A | 1.88e-03 | 187 | 30 | 3 | 6984_UP | |
| Drug | ikarugamycin; Up 200; 2uM; MCF7; HT_HG-U133A_EA | 1.91e-03 | 188 | 30 | 3 | 974_UP | |
| Drug | Naftopidil dihydrochloride [57149-08-3]; Down 200; 8.6uM; HL60; HT_HG-U133A | 1.94e-03 | 189 | 30 | 3 | 2911_DN | |
| Drug | Chlorambucil [305-03-3]; Down 200; 13.2uM; PC3; HT_HG-U133A | 1.94e-03 | 189 | 30 | 3 | 3788_DN | |
| Drug | 17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A | 1.94e-03 | 189 | 30 | 3 | 5586_UP | |
| Disease | banks of the superior temporal sulcus volume measurement | 1.35e-04 | 17 | 30 | 2 | EFO_0010286 | |
| Disease | nose morphology measurement | 3.31e-04 | 329 | 30 | 4 | EFO_0007843 | |
| Disease | retinitis pigmentosa (implicated_via_orthology) | 3.45e-04 | 27 | 30 | 2 | DOID:10584 (implicated_via_orthology) | |
| Disease | essential tremor | 3.55e-04 | 136 | 30 | 3 | EFO_0003108 | |
| Disease | prostate cancer (implicated_via_orthology) | 5.17e-04 | 33 | 30 | 2 | DOID:10283 (implicated_via_orthology) | |
| Disease | colorectal adenocarcinoma (is_implicated_in) | 5.82e-04 | 35 | 30 | 2 | DOID:0050861 (is_implicated_in) | |
| Disease | heart failure | 8.69e-04 | 185 | 30 | 3 | EFO_0003144 | |
| Disease | adipose tissue measurement | 9.63e-04 | 45 | 30 | 2 | EFO_0004764 | |
| Disease | QRS complex, QRS duration | 9.63e-04 | 45 | 30 | 2 | EFO_0005054, EFO_0005055 | |
| Disease | Acute Promyelocytic Leukemia | 1.01e-03 | 46 | 30 | 2 | C0023487 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| TPNSPEDYYTSLDND | 481 | Q99814 | |
| SPTNTQENPAYEEYI | 656 | Q99424 | |
| DDYVSEPQQEPCPYA | 481 | O14867 | |
| YNPEPYLNNESQPDS | 901 | O15013 | |
| TVESQQPFQPEYPDS | 1066 | Q6RI45 | |
| NDEIYDPQITSPYEN | 2916 | Q01484 | |
| DLSQPLEQYSPSYPD | 771 | P21802 | |
| SDENDNPPQFYPREY | 676 | Q96JQ0 | |
| PEAYQVPASYQPDEE | 221 | Q9BYM8 | |
| VYATTTPESDQPYPE | 161 | Q8TB73 | |
| PPDAYSTDTEYSQPE | 671 | Q8IVE3 | |
| PFEQPQEYDDPNATI | 101 | Q9NWB7 | |
| YRTNPEDIYPSNPTD | 161 | P16070 | |
| PAPSEYETSPEQLFY | 1236 | Q8TD84 | |
| YVYPDPTQEETYPSN | 221 | Q9HC77 | |
| TPQSQDPNPDEYYTE | 251 | P20908 | |
| PYVQPEDENYENDSV | 701 | Q9Y4J8 | |
| PSPGDTSYYQDQVDD | 36 | Q9NQZ2 | |
| TNPNIDPYDSYDPSV | 546 | O43815 | |
| YSEVPNFSEPNPDYR | 106 | Q96AH0 | |
| YPQEIDASSNYTPQD | 1021 | Q9HCM1 | |
| SEPTEPYLSSQNYGE | 1756 | Q6P2Q9 | |
| AAEETPPYSNYNTLP | 276 | Q13009 | |
| VYSEVPNFSEPNPEY | 101 | Q9BQ15 | |
| SEEDNPYTPTYQFPA | 431 | Q9BX66 | |
| SPEFESQSPRYEPQS | 111 | Q9H5H4 | |
| DFIQNYVDPTPDPNT | 176 | O43760 | |
| YNGQSENNEDYEIPP | 66 | Q96NM4 | |
| NPEYFPPASAVETEY | 966 | O15050 | |
| EPSQDYVPASQSYPG | 46 | O94900 | |
| ENNPDTPFDFTPENY | 46 | P19404 |